Moderna's Cancer Vaccine Clears Phase 3, Stock Surges 131%
In brief
- Moderna's intismeran autogene plus Keytruda met both primary endpoints in INTerpath-001 Phase 3 melanoma trial
- Stock surged 131% Wednesday to near $148, peaking at $163 intraday
- First positive Phase 3 win for personalized neoantigen and mRNA cancer therapy
- Combination outperformed Keytruda on recurrence-free and distant-metastasis-free survival
- Heavy short positioning triggered squeeze costing bearish traders ~$4.8 billion
The Trial Win
Moderna's Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its recurrence-free and distant-metastasis-free survival goals in patients with stage IIB–IV melanoma. The combination developed by Moderna and Merck beat Keytruda alone, the current standard of care, on both endpoints. This was the first positive Phase 3 result for a personalized neoantigen therapy, and the first for an mRNA-based cancer treatment.
Intismeran autogene works by personalizing the immune response. Doctors sequence a patient's tumor, map its unique mutations, and the mRNA teaches the body to manufacture neoantigens—custom tumor-fighting antigens tailored to that individual's cancer. That precision edge is why the result marks the first time a personalized neoantigen therapy showed a clinically meaningful edge over Keytruda in the adjuvant setting. The trial will continue to evaluate overall survival and other secondary endpoints not yet reported.
Market Reaction and Short Squeeze
Merck, the larger partner that sells Keytruda, also spiked on the news. But Moderna's move was the headline. The biotech carried one of the heaviest short bets among large caps, and Wednesday's surge triggered classic squeeze mechanics.
When a heavily shorted stock rockets, borrowers scramble to buy back shares to stop losses. That's the squeeze. With each shorted share now down almost $100, that is exactly the kind of pressure that can trigger a squeeze, according to Peter Hillerberg, ORTEX co-founder. The scale of Moderna's move left the short community scrambling.
